Clinical Trial: Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07714317) titled 'Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)' on July 15.

Brief Summary: The purpose of this phase Ib/II multicenter randomized control study is to investigate the efficacy and safety of peri-operative treatment with combination of CTLA-4, PD-1 antibodies and bevacizumab in resectable HCC

Study Start Date: July 20

Study Type: INTERVENTIONAL

Condition: Resectable Hepatocellular Carcinoma

Intervention: DRUG: IBI310+ sintilimab + bevacizumab

systemic therapy

DRUG: IBI310+ sintilimab

systemic therapy

DRUG: si...